Subcutaneous bupivacaine for treatment of spasticity: a case report.
In a previous report, we described heretofore undiscovered possibilities that neuropathic pain and spasticity may share some common pathophysiological mechanisms. Currently, systemically delivered local anesthetics are being used for the evaluation and treatment of neuropathic pain. We present a case describing the treatment of spasticity of spinal origin with continuous subcutaneous infusion of 0.75% bupivacaine in a patient who did not respond to traditional treatments and has become tolerant to intrathecal baclofen.
Goodman
B S
BS
Department of Rehabilitation Medicine, Emory University School of Medicine, Atlanta, GA.
Jann
B B
BB
Haddox
J D
JD
Denson
D
D
D000328:Adult; D002045:Bupivacaine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009128:Muscle Spasticity / Q000188:drug therapy; D010264:Paraplegia / Q000188:drug therapy*; D016896:Treatment Outcome
D002045:Bupivacaine